Odonate Therapeutics (ODTC) Key Ratios
$50,000.00
$49,998.50
(3,333,233.33%)
As on 01-Sep-2026 09:30EDT
Market cap
$53 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
7.3
P/B Ratio
0.5
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | 20.33 | 278.70 | -2.01 | 27.54 | 16.06 |
| Net Profit | -87.88 | 224.30 | -82.94 | 27.20 | 15.80 |
| EPS | -87.88 | 224.30 | -82.94 | 27.52 | 15.63 |
| Book Value | -- | -- | 7.21 | 0.36 | -6.53 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-23 | Dec-22 | Dec-21 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -3.09 | -34.41 | 7.01 | 53.64 | -69.92 |
| Return on Capital
| -2.81 | -33.72 | 6.84 | 51.26 | -66.52 |
| Return on Assets
| -0.50 | -27.96 | 6.84 | 47.00 | -55.34 |
| Debt to Equity (x)
| -- | -- | 0.02 | 0.03 | 0.08 |
Profitability
ROCE
6.84
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
6.84
|
51.26
|
-66.52
|
-82.63
|
-77.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
7.01
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
7.01
|
53.64
|
-69.92
|
-84.67
|
-78.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
6.84
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
6.84
|
47.00
|
-55.34
|
-70.84
|
-67.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
-2.01
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
-2.01
|
114.11
|
45.93
|
-12.99
|
-25.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-82.94
--
Year on year growth in profit after tax
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
-82.94
|
162.86
|
45.93
|
-12.99
|
-25.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
-0.83
--
Year on year growth in earnings per share
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
-0.83
|
1.63
|
0.31
|
0.11
|
-0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.02
--
Total debt / Net worth
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
0.02
|
0.03
|
0.08
|
0.04
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
0.00
|
0.00
|
0.01
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
111.72
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
111.72
|
82.66
|
4.75
|
5.91
|
7.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
226.11
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
226.11
|
169.81
|
2,512.96
|
6,245.15
|
12,635.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
0.00
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.00
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-5.78
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Odonate Therapeutics (ODTC)
|
-5.78
|
-4.55
|
0.95
|
1.21
|
1.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
